EAACI/ENDA position paper on drug provocation testing.

Area of Science:

• Clinical Immunology
• Pharmacology
• Allergy Diagnostics

Background:

• Drug hypersensitivity diagnosis relies on drug provocation testing (DPT), the established gold standard.
• Risk stratification is increasingly vital for tailoring DPT strategies, enhancing patient safety.
• Skin tests are generally recommended prior to DPT but can be omitted in defined low-risk patient groups.

Purpose of the Study:

• To provide guidance on optimizing drug provocation testing (DPT) use.
• To define criteria for omitting skin tests before DPT in low-risk patients.
• To balance diagnostic benefits with patient safety and resource allocation.

Main Methods:

• Development of an algorithm for adjusting DPT based on risk, informed by beta-lactam antibiotic allergy studies.
• Review of evidence for skin test validation and DPT necessity for various drug classes.
• Discussion of specific DPT considerations for chemotherapeutics, biologics, contrast media, anesthetics, proton pump inhibitors, anticonvulsants, and corticosteroids.

Main Results:

• An algorithm is presented for risk-adjusted DPT and selective omission of skin tests, particularly for beta-lactam antibiotics.
• DPT is frequently necessary for antibiotics (other than beta-lactams), NSAIDs, and other drugs due to poor skin test validation.
• Recommendations are made for DPT with chemotherapeutics, biologics, contrast media, and anesthetics, emphasizing specialized centers for the latter.

Conclusions:

• Optimized DPT strategies, incorporating risk stratification, improve diagnostic accuracy and patient safety.
• Skin tests can be safely omitted in carefully selected low-risk patients, streamlining the diagnostic process.
• This position paper offers recommendations for judicious DPT use across diverse drug classes, considering clinical evidence and resource management.